2020
DOI: 10.1091/mbc.e19-12-0704
|View full text |Cite
|
Sign up to set email alerts
|

HEXIM1 controls P-TEFb processing and regulates drug sensitivity in triple-negative breast cancer

Abstract: The positive transcription elongation factor b (P-TEFb), composed of CDK9 and cyclin T, stimulates transcriptional elongation by RNA polymerase (Pol) II and regulates cell growth and differentiation. Recently, we demonstrated that P-TEFb also controls the expression of EMT regulators to promote breast cancer progression. In the nucleus, more than half of P-TEFb are sequestered in the inactive state 7SK snRNP complex. Here, we show that the assembly of the 7SK snRNP is preceded by an intermediate complex betwee… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 8 publications
(7 citation statements)
references
References 48 publications
1
6
0
Order By: Relevance
“…Recently, the formation of CDK9-Cyclin T1-HSP90 complex was confirmed to be an active form of P-TEFb by using sequential immunoprecipitations in breast cancer cells. 28 Taken together, these data confirmed that the formation of the HSP90-CDC37-P-TEFb complex was increased under the BETi treatment in cells.…”
Section: Cdk9 Displays Increased Interactions With Hsp90 and Cdc37 Up...supporting
confidence: 63%
See 1 more Smart Citation
“…Recently, the formation of CDK9-Cyclin T1-HSP90 complex was confirmed to be an active form of P-TEFb by using sequential immunoprecipitations in breast cancer cells. 28 Taken together, these data confirmed that the formation of the HSP90-CDC37-P-TEFb complex was increased under the BETi treatment in cells.…”
Section: Cdk9 Displays Increased Interactions With Hsp90 and Cdc37 Up...supporting
confidence: 63%
“…Furthermore, with the treatment of a different BET inhibitor, iBET-151, we also observed increased interactions between HSP90/CDC37 and CDK9/Cyclin T1 in a dose-dependent manner (Figure D). Recently, the formation of CDK9-Cyclin T1-HSP90 complex was confirmed to be an active form of P-TEFb by using sequential immunoprecipitations in breast cancer cells . Taken together, these data confirmed that the formation of the HSP90-CDC37-P-TEFb complex was increased under the BETi treatment in cells.…”
Section: Resultsmentioning
confidence: 57%
“…Moreover, the CDK9-cyclin T1 complex controls the expression of EMT regulators to promote TNBC progression. 54 To explore the mechanism of activity of Compound 1 against TNBC, we detected EMT and CSC biomarkers by ChIP, qPCR, Western blotting, and flow cytometric analysis. Pleasingly, compound 1 showed promising activity against decreasing EMT and CSC biomarkers with comparable activity compared to the clinical CDK inhibitor dinaciclib ( 15 ).…”
Section: Discussionmentioning
confidence: 99%
“…Fourth, we found a variant rs201018268 located in the exonic region of HEXIM1. HEXIM1 is a transcription regulator suggested for its role in cancer [45,46] and linked to insomnia [21], but its association with MDD still lacks. It is worth further study to investigate whether variation in the exonic region of HEXIM1 affects MDD phenotype.…”
Section: Discussionmentioning
confidence: 99%